Works by Zhang, Lianglin


Results: 20
    1
    2
    3
    4
    5
    6
    7

    PARP1-SNAI2 transcription axis drives resistance to PARP inhibitor, Talazoparib.

    Published in:
    Scientific Reports, 2022, v. 12, n. 1, p. 1, doi. 10.1038/s41598-022-16623-3
    By:
    • Ding, Xia;
    • Zhu, Zhou;
    • Lapek, John;
    • McMillan, Elizabeth A.;
    • Zhang, Alexander;
    • Chung, Chi-Yeh;
    • Dubbury, Sara;
    • Lapira, Jennifer;
    • Firdaus, Sarah;
    • Kang, Xiaolin;
    • Gao, Jingjin;
    • Oyer, Jon;
    • Chionis, John;
    • Rollins, Robert A.;
    • Li, Lianjie;
    • Niessen, Sherry;
    • Bagrodia, Shubha;
    • Zhang, Lianglin;
    • VanArsdale, Todd
    Publication type:
    Article
    8
    9
    10
    11
    13
    14
    15

    Peptide Targeting of Tumor Lymph Vessels.

    Published in:
    Annals of the New York Academy of Sciences, 2008, v. 1131, p. 37, doi. 10.1196/annals.1413.003
    By:
    • Laakkonen, Pirjo;
    • Zhang, Lianglin;
    • Ruoslahti, Erkki
    Publication type:
    Article
    16
    17
    18
    19
    20

    Characterization of 11 human sarcoma cell strains.

    Published in:
    Cancer (0008543X), 2002, v. 95, n. 7, p. 1569, doi. 10.1002/cncr.10879
    By:
    • Hu, Mei;
    • Nicolson, Garth L.;
    • Trent, Jonathan C.;
    • Yu, Dihua;
    • Zhang, Lianglin;
    • Lang, Aiqing;
    • Killary, Ann;
    • Ellis, Lee M.;
    • Bucana, Corazon D.;
    • Pollock, Raphael E.
    Publication type:
    Article